# The evolution of personalized stroke thrombectomy

**Authors:** Emmanuel O. Mensah, Yew-Weng Fong, Sandeep Muram, Christopher S. Ogilvy, Philipp Taussky

PMC · DOI: 10.3389/fsurg.2025.1590146 · 2025-07-29

## TL;DR

This paper reviews how personalized stroke thrombectomy can be adapted to a wider range of patients, using new imaging and techniques to improve outcomes.

## Contribution

The paper introduces strategies for personalizing stroke thrombectomy based on lesion characteristics, patient factors, and procedural innovations.

## Key findings

- Personalized thrombectomy considers factors like infarct size, low NIHSS scores, and unique biomarkers.
- Procedural innovations include tailored device use and alternative access strategies for complex cases.
- Future improvements involve advanced imaging, biomarkers, and optimized devices for underrepresented populations.

## Abstract

Stroke is a leading cause of disability and death worldwide, with acute ischemic stroke accounting for most cases. Mechanical thrombectomy is a widely accepted treatment modality in appropriately selected patients, demonstrating improved functional outcomes through safe and effective recanalization. However, traditional trials have focused on a narrow subset of patients, limiting its applicability to diverse populations who would otherwise benefit from thrombectomy. Advances in neurovascular imaging, device innovation, and procedural techniques are driving a paradigm shift toward personalized stroke thrombectomy. This review explores personalization strategies across various domains, including lesion-specific considerations such as medium vessel occlusions (MeVOs), basilar artery occlusions (BAOs), and tandem lesions, as well as patient-specific factors like infarct size, low NIHSS scores, advanced age, and unique biomarkers. Additionally, we discuss procedural innovations, such as tailored device use and alternative access strategies to address anatomical and clinical complexities. While substantial progress has been made, challenges remain in refining patient selection criteria, mitigating procedural risks, and ensuring equitable access to thrombectomy. Future directions include taking full advantage of advanced imaging modalities, incorporating biomarkers for personalized care, and optimizing thrombectomy devices to support the use of thrombectomy in underrepresented populations. Precision thrombectomy has the potential to be adapted to a broader spectrum of patients, improving outcomes and ultimately reducing the global burden of stroke.

## Linked entities

- **Diseases:** stroke (MONDO:0005098)

## Full-text entities

- **Genes:** PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, FBN2 (fibrillin 2) [NCBI Gene 2201] {aka CCA, DA9, EOMD}
- **Diseases:** neurologic deterioration (MESH:D009422), thrombocytopenic (MESH:D013921), vasospasm (MESH:D020301), acute infarcts (MESH:D056989), brain tissue injury (MESH:D001930), Stroke (MESH:D020521), dissection (MESH:D000784), non-cognitive impairments (MESH:D003072), orthopedic (MESH:D009140), Mortality (MESH:D003643), Inflammatory (MESH:D007249), ATTENTION (MESH:D001289), dysarthria (MESH:D004401), atherosclerosis (MESH:D050197), M1 occlusion (MESH:D015470), M2 branch occlusions (MESH:D012170), gaze palsy (MESH:C565077), numbness (MESH:D006987), embolic complications (MESH:D004617), disability (MESH:D009069), coronary heart disease (MESH:D003327), dysphagia (MESH:D003680), LVO (MESH:C536223), hemiplegia (MESH:D006429), TICI 2C (MESH:C564684), cranial nerve defects (MESH:D003389), gait ataxia (MESH:D020234), vascular damage (MESH:D057772), infarct (MESH:D007238), thrombosis (MESH:D013927), collagen vascular disease (MESH:D014652), locked-in syndrome (MESH:D000080422), heart failure (MESH:D006333), pneumonia (MESH:D011014), dizziness (MESH:D004244), AIS (MESH:D000083242), intracranial hemorrhage (MESH:D020300), BAOs (MESH:D001157), cerebral edema (MESH:D001929), hyperglycemia (MESH:D006943), endocarditis (MESH:D004696), NIHSS (MESH:C538175), hypertension (MESH:D006973), ICA Dolichoarteriopathy (MESH:D002340), weakness (MESH:D018908), permanent disability (MESH:D003638), stenosis (MESH:D003251), cancer (MESH:D009369), atrial fibrillation (MESH:D001281), intracranial bleeding (MESH:D013345), thromboembolic (MESH:D013923), bleeding (MESH:D006470), ischemic damage (MESH:D017202), atherosclerotic plaque (MESH:D058226), Ischemic Strokes (MESH:D002544), aphasia (MESH:D001037), neurological deficit (MESH:D009461), ACA, MCA, and PCA occlusions (MESH:D020244), ischemic (MESH:D002545), hyperlipidemia (MESH:D006949)
- **Chemicals:** rivaroxaban (MESH:D000069552), blood glucose (MESH:D001786), glucose (MESH:D005947), creatinine (MESH:D003404), BGC (-), uric acid (MESH:D014527)
- **Species:** Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12344948/full.md

---
Source: https://tomesphere.com/paper/PMC12344948